u/naomi_erdogan

Yeah, 503A and 503B are different regulatory animals.

sock puppet accounts ask the same leading questions

Mechanistically the bit that matters is TRIUMPH. It explains most of the early profile and a decent chunk of the outcome.

the glucagon component changes the side effect profile, not just the efficacy

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

the the UK situation is different from the US, different regulations

This is correct. The injection-site soreness is horrible for three weeks and then just ends.

Research use material only, no human-use approval anywhere.

Yes, exactly this, and it is the bit that took me 3 weeks to accept.

Apotheke costs in New Zealand this month

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

Resting heart rate up 5 bpm from baseline, settled back down once I stopped escalating. Tracked daily so I am confident.

shortage list status is compounding, check the actual list

Strongly agree. The dispute resolved and the record stayed updated.

The heart rate signal in TRIUMPH is real and concerning.

Disagree on that part. 93.7% and 99.3% on the same vial is normal.

Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.

heart rate and dose escalation need actual measurements, not impressions

Yes, exactly this, and it is the bit that took me 72 weeks to accept.

reimbursement reality differs sharply

TRIUMPH phase 2 showed 99.0% weight loss but the reflux profile on the highest arm was rough. Phase 2 != phase 3.

Same experience. Week 68 and it simply stopped. I know that is not useful information but it is what happened.

the BCH situation resolved, logged it here as resolved